Severe sepsis is a disease with a high mortality. Development of shock is a most serious
complication and increases the risk of death considerably. Application of low dose
hydrocortisone is currently recommended only in patients after severe septic shock has been
established. Hydrocortisone therapy has a hemodynamic stabilizing effect and may reverse
shock, however, the preventive application has not been investigated in a larger study. The
study investigates whether low dose hydrocortisone prevents the development of shock in
patients with severe sepsis. It is postulated that shock prevention may also affect morbidity
and mortality.
Phase:
Phase 3
Details
Lead Sponsor:
Charite University, Berlin, Germany
Collaborators:
Coordination Centre for Clinical Trials Leipzig German Competence Network Sepsis German Federal Ministry of Education and Research SepNet - Critical Care Trials Group